Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/20.500.12008/39065
Cómo citar
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Rammauro, Florencia | - |
dc.contributor.author | Carrión Runco, Federico Daniel | - |
dc.contributor.author | Olivero-Deibe, Natalia | - |
dc.contributor.author | Fló Díaz, Martín | - |
dc.contributor.author | Ferreira, Ana María | - |
dc.contributor.author | Pritsch, Otto | - |
dc.contributor.author | Bianchi, Sergio | - |
dc.date.accessioned | 2023-08-07T17:32:57Z | - |
dc.date.available | 2023-08-07T17:32:57Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Rammauro, F, Carrión Runco, F, Olivero-Deibe, N, [y otros autores]. "Humoral immune response characterization of heterologous prime- boost vaccination with CoronaVac and BNT162b2" [Preprint] 2022. 8 h. | es |
dc.identifier.uri | https://hdl.handle.net/20.500.12008/39065 | - |
dc.description | Publicado en: Vaccine, 2022, 40(35):5189-5196. DOI 10.1016/j.vaccine.2022.07.023 | es |
dc.description.abstract | Background: Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has proven to be a successful strategy for prevent severe infections. CoronaVac and BNT162b2 are the most used vaccines worldwide, but their use in heterologous vaccination schedules is still subjected to evaluation. Methods: Fifty healthy individuals who received heterologous prime-boost vaccination with CoronaVac and BNT162b2 were enrolled in a post-vaccination serological follow-up longitudinal prospective study. We evaluated specific serum anti-receptor binding domain (RBD) IgG antibody levels, and their capacity to block RBD-ACE2 interaction with a surrogate neutralization assay. In 20 participants, we assessed antibody binding kinetics by surface plasmon resonance, and Fc-mediated functions by ADCC and ADCP reporter assays. Results: Our baseline seronegative cohort, displayed seroconversion after two doses of CoronaVac and an important decrease in serum anti-RBD IgG antibodies levels 80 days post-second dose. These levels increased significantly early after the third dose with BNT162b2, but 73 days after the booster we found a new fall. Immunoglobulin functionalities showed a similar behavior. Conclusions: The heterologous prime-boost vaccination with CoronaVac and BNT162b2 generated an impressive increase in serum anti-RBD specific antibody levels followed by a drop. Nevertheless, these titers remained well above those found in individuals only vaccinated with CoronaVac in the same elapsed time. Serum IgG levels showed high correlation with antibody binding analysis, their capacity to block RBD-ACE2 interaction, and Fc-effectors mechanisms. Our work sheds light on the humoral immune response to heterologous vaccination with CoronaVac and BNT162b2, to define a post vaccination correlate of protection against SARS-CoV-2 infection and to discuss the scheduling of future vaccine boosters in general population | es |
dc.description.sponsorship | Agencia Nacional de Investigación e Innovación y Comisión Académica de Posgrado (CAP), Universidad de la República. | es |
dc.format.extent | 8 h. | es |
dc.format.mimetype | application/pdf | es |
dc.language.iso | en_US | es |
dc.rights | Las obras depositadas en el Repositorio se rigen por la Ordenanza de los Derechos de la Propiedad Intelectual de la Universidad de la República.(Res. Nº 91 de C.D.C. de 8/III/1994 – D.O. 7/IV/1994) y por la Ordenanza del Repositorio Abierto de la Universidad de la República (Res. Nº 16 de C.D.C. de 07/10/2014) | es |
dc.subject | SARS-CoV-2 | es |
dc.subject | Heterologous vaccination | es |
dc.subject | Humoral immune response | es |
dc.subject | Binding kinetics | es |
dc.subject | Fc-mediated functions | es |
dc.title | Humoral immune response characterization of heterologous prime- boost vaccination with CoronaVac and BNT162b2 | es |
dc.type | Preprint | es |
dc.contributor.filiacion | Rammauro Florencia, Instituto Pasteur (Montevideo). | - |
dc.contributor.filiacion | Carrión Runco Federico Daniel, Instituto Pasteur (Montevideo). | - |
dc.contributor.filiacion | Olivero-Deibe Natalia, Instituto Pasteur (Montevideo). | - |
dc.contributor.filiacion | Fló Díaz Martín, Instituto Pasteur (Montevideo). | - |
dc.contributor.filiacion | Ferreira Ana María, Universidad de la República (Uruguay). Facultad de Ciencias. Instituto de Química Biológica. | - |
dc.contributor.filiacion | Pritsch Otto, Instituto Pasteur (Montevideo). | - |
dc.contributor.filiacion | Bianchi Sergio, Instituto Pasteur (Montevideo). | - |
dc.rights.licence | Licencia Creative Commons Atribución - No Comercial - Sin Derivadas (CC - By-NC-ND 4.0) | es |
Aparece en las colecciones: | Publicaciones académicas y científicas - Facultad de Ciencias |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | ||
---|---|---|---|---|---|
101016jvaccine202207023pp.pdf | 783,5 kB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons